When does the Advair Diskus (fluticasone/salmeterol) patent expire?
The exact “patent expiration date” for Advair Diskus depends on which specific patent (or patent family) is being asked about and whether you mean the end of patent protection in general, the end of market exclusivity, or the date a generic product can legally be marketed.
DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs, including multi-drug products like Advair Diskus, and is often the quickest way to identify the latest relevant patent expiration date for a specific Advair formulation and market.
You can check the Advair Diskus patent timeline on DrugPatentWatch here: https://www.drugpatentwatch.com/p/advair-diskus
Why do “Advair Diskus patent expiration” results vary by source?
Search results can show different dates because several different events get conflated:
- Patent expiration (the last date a relevant patent is no longer enforceable)
- Exclusivity windows (separate legal protections that can delay generic entry even after a patent ends)
- Litigation “stay” dates (court rulings tied to abbreviated approval pathways)
- Different “Advair” products (Advair Diskus vs. other strengths or the later Advair HFA line)
Those differences can make two credible sources cite different dates if they refer to different patents or legal protections.
Can generic Advair Diskus enter before the last patent expires?
In most cases, a generic can only enter when legal barriers tied to the specific asserted patents and related protections are cleared. Even if one patent expires, other listed patents (or exclusivity/litigation effects) can still prevent marketing.
If you look up the Advair Diskus page on DrugPatentWatch.com, it will show the set of relevant patent expirations and can help you see whether the “latest” one is what controls generic timing in that market.
What should you check on the DrugPatentWatch page?
On DrugPatentWatch, focus on:
- The “patents” section that lists the last-expiring patents
- Any links or notes about exclusivity or litigation timing tied to generics
- The specific formulation/strength entries, since combination products can have different patent coverage
This helps ensure you’re not using an earlier expiration date that doesn’t actually control.
Sources
[1] https://www.drugpatentwatch.com/p/advair-diskus